CF
ATNM icon

Centaurus Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

Centaurus Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97
Closed -$2K – 630
2018
Q2 		$2K Buy
+97
New +$1.23K ﹤0.01% 1983

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Centaurus Financial's ATNM Position: Q3 2018 in Review

Centaurus Financial sold out of Actinium Pharmaceuticals (ATNM) in Q3 2018, closing a stake of 97 shares — an estimated $2K sold.

Centaurus Financial first reported a position in ATNM in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 42 funds tracked by Wall St. Rank hold ATNM as of Q3 2018.

  • Centaurus Financial reported no remaining Actinium Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 97 Actinium Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Centaurus Financial first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Actinium Pharmaceuticals position peaked at $2K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.